Indaptus Therapeutics Inc.

Indaptus Therapeutics (INDP) is a public biopharmaceutical company focused on oncology. The Company’s proprietary platform is based on years of research findings that bacterial infections have the ability to interact with the immune system to induce tumor regression. Indaptus’ novel insights have enabled them to create attenuated and killed, non-pathogenic, gram-negative bacteria that can safely prime and activate innate and adaptive immune pathways. Lead candidate, Decoy20, has demonstrated anti-tumor and anti-viral activity in pre-clinical models and advancing into the clinic in 2022. 

Nasdaq: INDP
IR Website:
Headquarters: New York, NY

Content provided by Indaptus Therapeutics on 3-4-22.


The Indaptus Therapeutics management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.


Investor Presentation

Management Overview

Risks & Disclosures